|
JPT, IUCT and LEITAT Announce Collaboration on the Development of Novel Biofocused Anticancer Therapies (NOBITAN) Berlin, Germany, January 17, 2012 – JPT Peptide Technologies GmbH (JPT), a wholly-owned sub-sidiary of BioNTech AG (Mainz, Germany), IUCT and LEITAT (Barcelona, Spain) announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofo-cused targeting of nucleoside analogs linked to small cyclic peptidomimetics. The goal of the part-nership is to create novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile by selectively targeting inactive cytotoxic compounds toward tumor cells. The collaboration combines JPT’s proven and long term track record in executing peptide based hit identification and hit-to-lead projects with IUCT’s and LEITAT’s key expertise in biotechnological synthesis of nucleo-side analogs and activity screening studies. IUCT participó en el V - Campus de Excelencia Sesión 5.- RETOS DE LA BIOTECNOLOGIA EN LAS AREAS SANITARIAS , AGROALIMENTARIA E INDUSTRIAL Johan Diesenhoffer Premio Nobel |
News
Follow us on Social Networks
